Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | IDE | P14735 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370002 | 0.83 | LMNA (0.55) | CA1CA2CA9CA12CA4 | |
| SCHEMBL435704 | 0.83 | CA1 (0.73) | CA1CA2CA9CA12CA4 | |
| SCHEMBL8496857 | 0.81 | CA1 (0.70) | CA1CA2CA9CA12CA4 | |
| SCHEMBL248783 | 0.81 | CA1 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL29906360 | 0.81 | CA1 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL898422 | 0.80 | G6PD (0.64) | CA1CA2CA9CA12CA4 | |
| SCHEMBL755309 | 0.80 | LMNA (0.60) | ALDH1A1LMNAPTGS2MAPT | |
| SCHEMBL9806947 | 0.80 | CA1 (0.63) | CA1CA2CA9CA12CA4 | |
| SCHEMBL31208448 | 0.79 | CA1 (0.68) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5738131 | 0.79 | CA1 (0.68) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084232-B1 | DISPERSE AZO DYESTUFFS | DYSTAR COLOURS DISTRIB GMBH (DE) | 2012-08-15 | — | — | EP | claimed |
| US-7871446-B2 | Disperse azo dyestuffs | DyStar Colours Deutschland KG (DE) | 2011-01-18 | — | — | US | claimed |
| US-20100009081-A1 | 3-{[4-(2-Chloro-4-nitrophenylazo)-phenyl]-ethyl-amino}-2-methyl-propionic acid vinyl ester; ink jet printing; dyeing and printing of synthetic textile material and fiber blends; dyeings on polyester with improved washfastness properties obtained if dyestuffs contain a vinyl ester group in coupling | DYSTAR TEXTILFARBEN GMBH & CO. DEUTSCHLAND (DE) | 2010-01-14 | — | — | US | claimed |
| EP-2084232-A1 | DISPERSE AZO DYESTUFFS | DyStar Textilfarben GmbH & Co. Deutschland KG (DE) | 2009-08-05 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2008055846-A1 | DISPERSE AZO DYESTUFFS | DYSTAR TEXTILFARBEN GMBH & CO DEUTSCHLAND KG (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005100434-A1 | HALOGEN CONTAINING EPOXY COMPOSITIONS AND THEIR PREPARATION | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228080-A1 | Halogen containing epoxy compositions and their preparation | UNIVERSITY OF NORTH TEXAS (US) | 2005-10-13 | — | — | US | claimed |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | claimed |
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | claimed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-3945991-A | Heterocyclic azo compounds containing a quaternated hydrazide group | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3945989-A | Fluoro triazine containing water insoluble azo dyestuff | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3943120-A | WATER INSOLUBLE | CIBA-GEIGY AG (CH) | 1976-03-09 | — | — | US | disclosed |
| US-3933786-A | Heterocyclic-azo-phenyl compounds containing a styrl group | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | IRAK3, IRAK1, IRAK2 | CA1 4877/4885CA2 4848/4885CA9 4869/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA1 2828/4885CA2 3501/4885CA9 3772/4885 |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | SLC9A1, NHERF1, SLC9A5 | CA1 762/4885CA2 249/4885CA9 731/4885 |
| US-20100009081-A1 | 3-{[4-(2-Chloro-4-nitrophenylazo)-phenyl]-ethyl-amino}-2-methyl-propionic acid vinyl ester; ink jet printing; dyeing and printing of synthetic textile material and fiber blends; dyeings on polyester with improved washfastness properties obtained if dyestuffs contain a vinyl ester group in coupling | WDR77, PRMT7, CBR3 | CA1 4268/4885CA2 3639/4885CA9 3583/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA1 3047/4885CA2 2753/4885CA9 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.